Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC) — Stephen L. Chan (2017) | RDL Network
Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho-Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, E. Chen, A.B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng
Discussion(0)
No comments yet. Be the first to comment.